Corpus Intelligence IC Memo — BAYSTATE NOBLE HOSPITAL 2026-04-26 07:38 UTC
IC Memo — BAYSTATE NOBLE HOSPITAL
Investment Committee Memorandum | MA | 70 beds | Grade C | EBITDA uplift $5.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BAYSTATE NOBLE HOSPITAL

CCN 220065 | HAMPDEN, MA | 70 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BAYSTATE NOBLE HOSPITAL is a 70-bed under-performing / distressed in HAMPDEN, MA with $70.3M in net patient revenue and a -16.8% operating margin. The hospital serves a payer mix of 34.5% Medicare, 4.6% Medicaid, and 60.9% commercial.

Thesis: Turnaround. Our ML models identify $5.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -16.8% to -9.4% (+736bps).

Net Revenue HCRIS$70.3M
Current EBITDA COMPUTED$-11.8M
Operating Margin COMPUTED-16.8%
Occupancy HCRIS57.1%
Revenue / Bed COMPUTED$1.0M
Net-to-Gross HCRIS34.9%
Distress Probability ML47.6%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
43
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -16.8% places it below the state median. Among 43 size-comparable peers (35-140 beds), the median margin is -10.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (35-140), prioritizing same-state peers. 43 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BAYSTATE NOBLE HOSPITAL (Target)MA70$70.3M-16.8%
EMERSON HOSPITALMA111$315.1M-10.1%
MASSACHUSETTS EYE AND EAR INFIMA41$263.9M-36.1%
COOLEY DICKINSON HOSPITALMA118$233.6M2.3%
STURDY MEMORIAL HOSPITALMA125$221.7M-12.2%
NEW ENGLAND BAPTIST HOSPITALMA75$221.2M-4.6%
HEALTHALLIANCE-CLINTONMA125$190.6M-29.1%
FALMOUTH HOSPITALMA81$172.1M-2.2%
MORTON HOSPITALMA125$156.5M-6.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.5M+210bp18mo
Cost to Collect4.5%2.5%$1.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$856K+122bp9mo
Clean Claim Rate88.0%96.0%$45K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.5M
Cost to Collect
$1.4M
Denial Rate Reduction
$1.4M
A/R Days Reduction
$856K
Clean Claim Rate
$45K
Total EBITDA Uplift$5.2M
Current EBITDA$-11.8M
+ RCM Uplift+$5.2M
Pro Forma EBITDA$-6.6M
Current Margin-16.8%
Pro Forma Margin-9.4%
WC Released (1x)$2.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-18.1M$-26.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-18.1M$-34.5M0.00x-100.0%
Bull Case9.0x11.0x$-16.3M$-23.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-16.3M$-30.3M0.00x-100.0%
Bear Case11.0x10.0x$-20.0M$-46.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-20.0M$-57.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 43 hospitals with 35-140 beds
  • Same-state prioritization (n=44)
  • Comp margins: P25=-19.4% / P50=-10.8% / P75=0.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.